EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 9.2 www.in-academy.uz/index.php/ejmns

MODERN PHARMACEUTICAL TECHNOLOGIES FOR THE DEVELOPMENT OF PEDIATRIC DOSAGE FORMS

Kocherova Umida Anvarovna
4th-year Student, Faculty of Dentistry and Pharmacy,
Pharmacy Program, Alfraganus University, Tashkent, Uzbekistan
Usmonova Malika Komiljonovna
Scientific Supervisor: Acting Associate Professor (PhD),
Department of Pharmaceutical Sciences and Chemistry,
Alfraganus University, Tashkent, Uzbekistan
https://doi.org/10.5281/zenodo.22329989

ARTICLE INFO

Received: 24th August 2026
Accepted: 29th August 2026
Online: 30th August 2026

KEYWORDS

Pediatric medicines, pediatric dosage forms, pharmaceutical technology, oral liquid formulations, mini-tablets, taste masking, drug delivery, pediatric pharmacotherapy, 3D printing.

ABSTRACT

Pediatric patients represent a special population in pharmaceutical practice because physiological development, body weight, organ maturation, swallowing ability, taste preferences, and pharmacokinetic characteristics change considerably throughout childhood. Consequently, medicines developed primarily for adults cannot always be administered safely or conveniently to children. The development of appropriate pediatric dosage forms is therefore an important area of modern pharmaceutical technology. An effective pediatric formulation should provide accurate dosing, acceptable palatability, adequate chemical and physical stability, appropriate drug release, and ease of administration. This article reviews modern pharmaceutical technologies used in the development of pediatric dosage forms. Particular attention is given to oral liquid formulations, orally disintegrating tablets, mini-tablets, multiparticulate systems, modified-release formulations, orodispersible dosage forms, transdermal systems, and emerging technologies such as three-dimensional printing. The role of taste masking, dose flexibility, excipient selection, particle engineering, and patient-centered formulation design is also discussed. The advantages and limitations of different pediatric dosage forms are evaluated from pharmaceutical and technological perspectives. Modern formulation approaches provide opportunities to improve medication acceptability and dosing accuracy in children. However, pediatric drug development remains challenging because formulation characteristics must be adapted to different age groups and developmental stages. Careful selection of excipients, validated manufacturing processes, stability

assessment, and appropriate quality control are essential for producing safe and effective pediatric medicines. The integration of innovative technologies with patient-centered pharmaceutical development may contribute significantly to improving medication adherence and therapeutic outcomes in pediatric patients.

Introduction: Children are not simply smaller versions of adults. During childhood, substantial physiological and anatomical changes occur that can influence drug absorption, distribution, metabolism, and excretion. These developmental differences create specific requirements for pharmaceutical dosage forms intended for pediatric patients. The selection of an appropriate dosage form is particularly important in younger children. Infants and toddlers may have difficulty swallowing conventional tablets and capsules, while older children may be capable of using solid oral dosage forms but still experience problems with unpleasant taste, tablet size, or dose flexibility. Therefore, pharmaceutical technology plays an essential role in adapting medicines to the practical and physiological needs of different pediatric age groups. Historically, many medicines prescribed to children were available primarily as adult formulations. Healthcare professionals sometimes had to manipulate tablets, divide dosage forms, crush tablets, or prepare extemporaneous formulations to obtain an appropriate pediatric dose. Such practices may lead to dose variability, stability problems, inappropriate drug release, or administration difficulties.

Modern pediatric pharmaceutical development aims to overcome these limitations by designing dosage forms specifically for children. International regulatory initiatives have emphasized the importance of pediatric formulation development and age-appropriate dosage forms. The European Medicines Agency, for example, has published guidance concerning pharmaceutical development of medicines for pediatric use and emphasizes the importance of considering the needs of different pediatric populations. Pharmaceutical technology provides numerous approaches for this purpose. Liquid formulations can offer flexible dosing, while mini-tablets and multiparticulate systems may provide accurate doses without requiring conventional large tablets. Orally disintegrating dosage forms can facilitate administration without water. Taste-masking technologies can reduce the unpleasant sensory properties of active pharmaceutical ingredients. More recently, additive manufacturing and three-dimensional printing have attracted attention because they may allow the production of personalized dosage forms with adjustable drug doses, shapes, sizes, and release characteristics.

The objective of this article is to review modern pharmaceutical technologies used in the development of pediatric dosage forms and to evaluate their potential advantages, limitations, and future applications.

The development of pediatric medicines requires consideration of several factors that are less critical or different in adult pharmaceutical formulations.

1. The pediatric population includes several developmental stages, ranging from premature newborns and term neonates to infants, toddlers, children, and adolescents. Each group has different physiological and practical characteristics.

A formulation suitable for an adolescent may be inappropriate for a neonate. For example, a young child may not be able to swallow a conventional tablet, whereas an adolescent may prefer a solid dosage form because it is convenient and portable.

Therefore, pediatric pharmaceutical development should consider age-appropriate dosage forms rather than attempting to create one formulation for all children.

2. Pediatric doses are frequently calculated according to body weight or body surface area. Consequently, the required dose may vary substantially among patients.

A suitable pediatric dosage form should allow accurate adjustment of the administered dose. Oral liquids are particularly useful in this regard because the volume can be adjusted according to the prescribed dose.

However, liquid formulations may also present dosing errors when household spoons are used. The use of calibrated oral syringes can improve dose measurement and administration accuracy.

3. Taste is one of the most important factors affecting acceptance of medicines by children. Many active pharmaceutical ingredients have bitter, metallic, acidic, or otherwise unpleasant tastes.

Poor palatability can result in refusal, incomplete administration, and reduced adherence. Therefore, taste masking is an important component of pediatric pharmaceutical technology.

Taste-masking approaches include the use of sweeteners, flavors, polymers, lipid coatings, ion-exchange resins, microencapsulation, and complexation techniques.

4. The physical ability of a child to swallow and manipulate a dosage form changes with age. Large tablets and hard capsules may be difficult or unsafe for younger children.

Formulations should therefore be designed with appropriate dimensions, mechanical properties, and administration requirements.

5. Excipients that are routinely used in adult medicines may not always be suitable for all pediatric populations. Infants, particularly neonates, may be more vulnerable to certain excipients because of immature metabolic and elimination

pathways.Consequently, excipient selection should be based on safety, concentration, route of administration, age, and duration of exposure.

Oral liquid formulations are among the most widely used pediatric dosage forms because they provide dose

flexibility and can be administered to children who cannot swallow tablets. Solutions, syrups, suspensions, and emulsions can be formulated according to the physicochemical characteristics of the active pharmaceutical ingredient.

1. Solutions contain the active ingredient dissolved in an appropriate solvent or solvent system. They provide relatively uniform drug distribution when adequately formulated.

Their main advantage is that the drug is already dissolved, which can facilitate administration and absorption. However, poorly water-soluble active ingredients may not be suitable for conventional aqueous solutions.

2. Suspensions are particularly useful when the active ingredient has low aqueous solubility. The drug is dispersed as fine particles within a liquid vehicle.

An appropriately designed suspension should demonstrate acceptable sedimentation behavior, redispersibility, viscosity, particle-size distribution, and chemical stability.

Suspensions also require careful control of dose uniformity because inadequate shaking can lead to non-uniform drug distribution.

3. Syrups and flavored oral liquids can improve palatability. Sweeteners and flavoring agents may reduce the perception of bitterness and make administration more acceptable. Nevertheless, formulation scientists must consider sugar content, dental health, microbial stability, and the suitability of preservatives and sweeteners for the intended pediatric population.

4. Although oral liquids provide flexibility, they also have technological limitations. They may require preservatives, can be vulnerable to microbial contamination, may have relatively short stability after opening, and may require special storage conditions.

In addition, inaccurate measurement of liquid doses can lead to underdosing or overdosing. Therefore, appropriate measuring devices should be provided with pediatric liquid medicines.

Mini-tablets are small tablets specifically designed to provide pediatric doses while retaining several advantages of conventional solid dosage forms. Their small dimensions may make them easier to swallow than standard tablets. Mini-tablets can also be manufactured with different release characteristics and may be combined to provide flexible dosing. Multiparticulate systems include pellets, granules, microspheres, and other small units. These particles can sometimes be incorporated into liquids, soft foods, or other suitable vehicles, depending on the formulation.

An important advantage of multiparticulate systems is the possibility of distributing the drug across numerous individual units. This can reduce the consequences of dose variability associated with a single large dosage unit. Modified-release coatings can also be applied to pellets or granules. This creates opportunities for controlled drug release while maintaining a pediatric-friendly administration method.

However, compatibility with food and beverages must be evaluated carefully. The dosage form should not be administered with a vehicle that significantly alters drug release or

stability. Mini-tablets and multiparticulate systems therefore represent important alternatives to conventional tablets and capsules, particularly for children who have difficulty swallowing larger dosage forms.

Orally disintegrating tablets are designed to disintegrate rapidly in the oral cavity, reducing the need for swallowing an intact tablet with water.

This characteristic can be advantageous for pediatric patients who have difficulty swallowing conventional tablets. The development of orally disintegrating dosage forms requires careful optimization of disintegration time, mechanical strength, porosity, moisture sensitivity, and taste. Because the dosage form rapidly contacts taste receptors, taste masking may be particularly important. Pharmaceutical scientists may use polymeric coatings, complexation, ion-exchange techniques, microencapsulation, or appropriate flavor systems to improve palatability. Other orally disintegrating systems, including films and rapidly dissolving formulations, have also been investigated as patient-friendly dosage forms. The major advantages of these systems include portability, ease of administration, and reduced dependence on water. Nevertheless, moisture sensitivity and mechanical fragility can present manufacturing and packaging challenges.

Taste masking is a central aspect of pediatric formulation development. Many active pharmaceutical ingredients have unpleasant tastes, and children can be particularly sensitive to these sensory characteristics. If a formulation has poor taste, even a pharmacologically effective medicine may fail to achieve the desired therapeutic outcome because the patient refuses or incompletely consumes it.

Several technological approaches can be used to reduce unpleasant taste.

1. The simplest strategy involves adding sweeteners and flavors. Common pharmaceutical sweetening systems may include sucrose, sorbitol, xylitol, or other suitable agents.

Flavor selection should correspond to the target pediatric population. However, sweeteners alone may be insufficient for highly bitter active substances.

2. The active pharmaceutical ingredient can be coated with a polymeric material that reduces direct contact between the drug and taste receptors.

The coating should remain sufficiently stable during the short period of oral administration while allowing appropriate drug release after swallowing.

3. Microencapsulation surrounds drug particles with a protective coating. This technology can provide taste masking and may simultaneously modify drug release.

The final particle size and coating characteristics are important because excessively large particles may create an unpleasant mouthfeel.

4. Complex formation between the active ingredient and an appropriate pharmaceutical excipient may reduce the free concentration of the drug in saliva and consequently decrease bitterness.Cyclodextrins and ion-exchange resins are examples of materials investigated for this purpose.

Taste masking should therefore be viewed as a technological design parameter rather than merely a cosmetic modification.

Modified-release formulations are designed to alter the rate, location, or duration of drug release. For some medicines, prolonged release may reduce the frequency of administration and improve convenience. This can be particularly valuable for children and their caregivers. However, modified-release formulations require careful development because crushing, chewing, or otherwise manipulating certain dosage forms can destroy their release characteristics.

Multiparticulate systems may offer advantages in this context because individual pellets or granules can be coated to provide controlled release while allowing the overall dose to remain relatively flexible. The development of pediatric modified-release medicines must therefore balance pharmacokinetic requirements with practical administration considerations.A formulation that provides excellent controlled release but cannot be safely administered to a child does not represent an appropriate pediatric dosage form.

Three-dimensional printing is an emerging technology with significant potential for personalized pharmaceutical manufacturing. Unlike conventional mass manufacturing, 3D printing can potentially produce dosage forms with different doses, shapes, internal structures, and release characteristics without completely changing the manufacturing platform. This feature may be particularly valuable in pediatrics because children require doses that vary according to age, weight, and developmental stage.

Different printing approaches can potentially produce tablets with customized drug loads. The technology may also allow the production of formulations with complex internal geometries designed to influence dissolution and drug release.

Another potential advantage is the possibility of manufacturing visually attractive dosage forms that improve acceptability. Nevertheless, 3D printing remains associated with important challenges. These include manufacturing speed, reproducibility, raw-material requirements, printer qualification, dose uniformity, stability, and regulatory standardization. The transition of 3D-printed medicines from research laboratories to routine pharmaceutical practice will therefore require extensive validation and regulatory development.

Quality control is essential for ensuring that pediatric medicines provide the intended dose and therapeutic performance.

Important quality attributes depend on the dosage form but may include:

- appearance and physical characteristics;
- identification of the active pharmaceutical ingredient;
- assay and drug content uniformity;
- dissolution or drug-release characteristics;
- particle-size distribution;
- pH;
- viscosity;
- microbial quality;

- moisture content;
- stability;
- dose accuracy.

For oral liquids, viscosity and sedimentation behavior can influence dose uniformity and patient acceptability. For tablets, hardness, friability, disintegration, and dissolution are important parameters. Pediatric formulations should also be assessed under appropriate storage conditions to determine their shelf life and in-use stability. Packaging is another important aspect. Child-resistant packaging may be necessary to reduce accidental ingestion, while packaging should simultaneously permit caregivers to measure and administer the required dose conveniently. Thus, pharmaceutical quality control should evaluate not only the chemical quality of the drug product but also its practical suitability for pediatric use.

Modern pediatric dosage-form technologies provide several important benefits.

First, they can improve dose flexibility. This is especially important when doses are calculated according to body weight. Second, appropriate dosage forms can improve patient acceptability by reducing unpleasant taste and simplifying administration.

Third, advanced technologies can improve drug stability by protecting active pharmaceutical ingredients from environmental factors. Fourth, multiparticulate and modified-release systems can provide controlled drug release, potentially reducing administration frequency. Fifth, personalized manufacturing technologies such as 3D printing may provide opportunities for patient-specific dosing.

Sixth, age-appropriate formulations may reduce the need for caregivers to manipulate adult dosage forms. Together, these advantages demonstrate the important role of pharmaceutical technology in improving pediatric pharmacotherapy.

Despite technological progress, several challenges remain.

The first challenge is the diversity of the pediatric population. A formulation appropriate for a teenager may not be suitable for an infant. Pharmaceutical developers therefore need to consider multiple age groups.

The second challenge is taste. Developing a formulation that is both pharmacologically effective and acceptable to children can require extensive sensory and formulation studies. The third challenge is excipient safety. The selection of excipients must take developmental physiology into account.

The fourth challenge is dose accuracy. Flexible formulations must allow caregivers and healthcare professionals to administer the intended amount reliably.

The fifth challenge is stability. Pediatric formulations, particularly liquid preparations, may be sensitive to microbial contamination, temperature, light, or chemical degradation. Finally, innovative technologies must meet strict pharmaceutical quality requirements. Novel manufacturing methods cannot replace the fundamental requirements of identity, purity, potency, safety, stability, and reproducibility.

The future of pediatric pharmaceutical technology is likely to move toward increasingly patient-centered and personalized dosage forms. Digital manufacturing, 3D printing, advanced particle engineering, nanotechnology, and controlled-release systems may provide new opportunities for developing medicines adapted to individual pediatric needs. Personalized dosing could become particularly important for children with significant differences in body weight, metabolism, or therapeutic requirements.

Artificial intelligence and computational modeling may also contribute to formulation development by helping researchers predict drug-excipient interactions, optimize formulation composition, and evaluate manufacturing parameters. Another important direction is the development of child-friendly dosage forms that combine accurate dosing with pleasant sensory characteristics. Future pediatric pharmaceutical development should therefore integrate pharmaceutical science, clinical pharmacology, material science, regulatory science, and patient-centered design. The ultimate objective is not simply to produce a smaller version of an adult medicine but to develop a formulation that is scientifically appropriate, safe, effective, convenient, and acceptable for children.

Conclusion: Pediatric pharmaceutical technology is an important and rapidly developing field of modern pharmacy. Children have specific physiological, developmental, and practical requirements that must be considered during the design of medicines. Oral liquids, mini-tablets, multiparticulate systems, orally disintegrating dosage forms, modified-release formulations, and innovative technologies such as three-dimensional printing provide different approaches to addressing these requirements.

Among the most important formulation considerations are dose flexibility, palatability, ease of administration, excipient safety, drug stability, and reliable drug release. Taste-masking technologies are particularly important because unpleasant taste can negatively influence medication acceptance and adherence. Modern pharmaceutical technologies provide opportunities to reduce the need for manipulation of adult dosage forms and to develop medicines that are better adapted to individual pediatric patients. Nevertheless, significant challenges remain in relation to excipient safety, manufacturing scale-up, quality control, stability, regulatory requirements, and clinical validation. Continued research is necessary to translate promising laboratory technologies into safe and commercially available pediatric medicines. In conclusion, the development of age-appropriate pediatric dosage forms represents an important responsibility of pharmaceutical science. The combination of innovative formulation technologies and patient-centered development has the potential to improve medication administration, adherence, safety, and therapeutic outcomes in children.

References:

1. European Medicines Agency. Guideline on Pharmaceutical Development of Medicines for Paediatric Use. European Medicines Agency; 2013.
2. World Health Organization. Development of Paediatric Medicines: Points to Consider in Formulation. WHO Technical Report Series. Geneva: World Health Organization.
3. Krause J., Breitkreutz J. Improving drug delivery in paediatric medicine. Pharmaceutical Medicine. 2008;22:41–50.
4. Ivanovska V., Rademaker C.M.A., van Dijk L., Mantel-Teeuwisse A.K. Pediatric drug formulations: a review of challenges and progress. Paediatric Drugs. 2014;16:1–10.
5. Malkiel S., Harding R., Gaisford S. Mini-tablets: an emerging dosage form for pediatric drug delivery. Expert Opinion on Drug Delivery.
6. Klingmann V., Seiler L., Meissner T., Breitkreutz J. Acceptability of uncoated mini-tablets in young children. Journal of Pediatric Gastroenterology and Nutrition.
7. Preis M. Orally disintegrating films and mini-tablets: innovative dosage forms for pediatric patients. European Journal of Pharmaceutics and Biopharmaceutics.
8. Ranmal S., Cram A., Tuleu C. Age-appropriate and acceptable paediatric dosage forms: insights from children and caregivers. International Journal of Pharmaceutics.
9. Klingmann V., Seiler L., Meissner T., Breitkreutz J. Acceptability of multiple oral dosage forms in children. International Journal of Pharmaceutics.
10. European Medicines Agency. Reflection Paper: Formulations of Choice for the Paediatric Population. EMA.
11. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. ICH Harmonised Tripartite Guideline.
12. United States Food and Drug Administration. General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. FDA Guidance for Industry.
13. Samy R., et al. Three-dimensional printing technologies for pharmaceutical applications and personalized medicine. International Journal of Pharmaceutics.
14. Preis M., Breitkreutz J. Pediatric drug delivery: current strategies and future perspectives. Expert Opinion on Drug Delivery.
15. Tuleu C., et al. Formulation and acceptability of medicines for children: current challenges and emerging approaches. Advanced Drug Delivery Reviews.